News

UK Phage Therapy announces a collaboration with CPI, Fixed Phage, and the University of Leicester to establish Phage therapy infrastructure in the UK.

BioChimPharm, a Georgian biopharmaceutical company, announces the completion of the modernization and renovation of its historic phage manufacturing facility, which was originally built in 1934.

Fixed Phage secures further £1.5m investment to scale programmes in Animal & Veterinary Health and Human Health.

MicroMir shares results for the efficiency of oral and inhalation bacteriophage cocktails in their Post-Covid phage therapy rehabilitation study.

Phage-UK is now live. It is a network for clinicians and phage researchers that work together to help build a path for phage therapy to be accessible to patient based in the United Kingdom.

Creative Biolabs provides an overview of a study that looks into the possibility of bacteriophages monitoring their hosts.

Overview on recent developments in phage clinical trials – BiomX BX002, Adaptive Phage Therapeutics DANCE, Locus Biosciences LBP-EC001 and NIAID with ARLG WRAIR-PAM-CF1.

Creative Biolabs shares insights on bacteriophage therapy to treat acne caused by specific strains of Cutibacterium acnes.

Creative Biolabs shares an outlook on the use of bacteriophages as a Tuberculosis diagnostic tool for the detection of TB infection.

Developments surrounding phage therapy in Australia have been approved to regulate the process of phage therapy, rather than a specific phage product.